In this video, Jay Chhablani, MD, director of clinical research at the UPMC Vision Institute, professor of ophthalmology and ...

ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

Gold nanoparticles show promise in helping restore vision in people with retinal disorders like macular degeneration.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.